Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme

6Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

The biology of recurrent glioblastoma multiforme (GBM) is a dynamic process influenced by selection pressure induced by different antitumoural therapies. The poor clinical outcome of tumours in the recurrent stage necessitates the development of effective therapeutic strategies. Checkpoint-inhibition (PD1/PD-L1 Inhibition) is a hallmark of immunotherapy being investigated in ongoing clinical trials. The purpose of this study was to analyse the PD-L1 expression in de-novo and recurrent glioblastoma multiforme and to explore associated genetic alterations and clinical traits. We show that PD-L1 expression was reduced in recurrent GBM in comparison to de-novo GBM. Additionally, patients who received an extended dose of temozolomide (TMZ) chemotherapy showed a significantly reduced level of PD-L1 expression in the recurrence stage compared to the corresponding de-novo tumour. Our findings may provide an explanation for potentially lower response to immunotherapy in the recurrent stage due to the reduced expression of the therapeutic target PD-L1.

Cite

CITATION STYLE

APA

Heynckes, S., Gaebelein, A., Haaker, G., Grauvogel, J., Franco, P., Mader, I., … Heiland, D. H. (2017). Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme. Oncotarget, 8(43), 74170–74177. https://doi.org/10.18632/oncotarget.18819

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free